UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023568
Receipt number R000027143
Scientific Title The study of TOpiroxostat for Possible benefits
Date of disclosure of the study information 2016/08/09
Last modified on 2019/03/04 18:24:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of TOpiroxostat for Possible benefits

Acronym

The study of TOpiroxostat for Possible benefits (TOP-A Study)

Scientific Title

The study of TOpiroxostat for Possible benefits

Scientific Title:Acronym

The study of TOpiroxostat for Possible benefits (TOP-A Study)

Region

Japan


Condition

Condition

Hyperuricemia complicated with diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Using CAVI for measuring the effects on arteriosclerosis among hyperuricemic patients with diabetes who are administered with topiroxostat is examined. Also, blood XOR activity and serum uric acid are measured to examine the relations to arteriosclerosis and medications.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1. Amount of change in CAVI at the week 24
2. Amount and percent change in blood XOR activity at the 24 week

Key secondary outcomes

1. Index for hyperuricemia: amount of changes in serum uric acid levels , and the amount and percent changes of blood XOR activity
2. Index for arteriosclerosis: changes in CAVI and hsCRP values
3. Index for renal function: change in eGFR, and the amount and rate of changes in ACR (urine albumin/Cr ratio)
4. Index for acid stress: changes in d-ROM, and MDA-LDL
5. Changes in general blood and urine tests items, body weight, BMI, blood pressure, and pulse
6. All measured raw data listed above
7. Incidence rate of abnormality found in liver function tests
8. Frequencies of the occurrence of gouty arthritis attack during the study
9. Correlation between CAVI and blood XOR activity


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Topiroxosta:
Topiroxostat is orally taken twice a day after breakfast and supper for 24 weeks. At every observation point, patients visit hospital without taking and test are performed. Responsible investigator and investigators change dose of topiroxostat accordingly to the results of the tests.

Topiroxostat is gradually increased by 40 mg/day every 6 weeks starting from 40 mg/day if a serum uric acid level doesn't fall below 3.0 m/dL. If a serum urine acid level becomes< 3.0 m/dL, the amount of topiroxostat is back to the previous amount.

However, whenever gouty arthritis is admitted during the study, the investigator may stop increasing the amount or suspend the administration of topiroxostat until the symptom disappears.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

80 years-old >

Gender

Male

Key inclusion criteria

Patients who meet all of the following criteria are included in this study.
1. Male with hyperuricemia
2. Patients aged at 50 years or older, and younger than 80 years at the time of giving their consent
3. Type 2 diabetic patients with HbA1c lower than 9.0% during the last 12 weeks from the consent
4. Patients who are with a uric acid level 7.0 mg/dL or higher and without any medication for hyperuricemia, or hyperuricemic patients who are currently using benzbromarone
5. Patients with ability of giving their written consent

Key exclusion criteria

Patients who fall into any of the following criteria are excluded from participating in the study.
1. Female
2. Patients complicated with arteriosclerosis obliterans, or ABI 0.9 or lower
3. Complicated with atrial fibrillation
4. Using any type of insulin treatment
5. Using any type of SGLT2 inhibitors
6. Patients with gouty arthritis at baseline
7. Patients who may show hypersensitiveness to topiroxostat
8. Patients who are currently on mercaptopurine hydrate or azathioprine, or planning to take one of them
9. Patients with liver function failure or cirrhosis of the liver
10. Patients complicated with chronic liver hepatitis (type B, or C), and classified as active hepatitis
11. Patients with kidney stone, or severe renal function failure
12. Patients with malignant tumor (excluding those completely cured)
13. Other conditions that investigators judge to be inappropriate to join the study

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ichiro Tatsuno

Organization

Toho University Medical Center Sakura Hospital

Division name

Center of Diabetes, Endocrinology and Metabolism

Zip code


Address

564-1 Shimoshizu, Sakura, Chiba

TEL

043-462-8811

Email

ichiro.tatsuno@med.toho-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroki Takayama

Organization

Soiken Inc.

Division name

Clinical Study Support Division

Zip code


Address

NBF Ogawamachi Building 4F, 1-3-1 Ogawamachi, Kanda, Chiyoda-ku, Tokyo

TEL

03-3295-1350

Homepage URL


Email

takayama@soiken.com


Sponsor or person

Institute

Toho University Medical Center Sakura Hospital

Institute

Department

Personal name



Funding Source

Organization

SANWA KAGAKU KENKYUSHO CO. LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 08 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 02 Month 04 Day

Date of IRB


Anticipated trial start date

2016 Year 09 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 08 Month 09 Day

Last modified on

2019 Year 03 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027143


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name